Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ASC4FIRST
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
- NCT04971226 ↗
- Active, not recruiting
- Novartis Pharmaceuticals
- Deep
We haven't built an HCP commentary report on ASC4FIRST (asciminib in newly diagnosed Ph+ chronic-phase chronic myeloid leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ASC4FIRST so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 35 | |
| YouTube | 19 | |
| Podcasts | 16 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Interventions
- Imatinib; Nilotinib; Bosutinib; Dasatinib; Asciminib
- Arms
- Asciminib · Experimental
- Investigator selected TKIs · Active comparator
- Enrollment
- 405
- Primary outcomes
- Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI
- Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Asciminib (Imatinib Stratum) vs Investigator Selected TKI (Imatinib Stratum)
- Sponsor
- Novartis Pharmaceuticals
- Start
- Oct 6, 2021
- Primary completion
- Nov 28, 2023
- Results posted
- Yes
- Registry record
- NCT04971226 · updated Aug 28, 2026
Publications
linked from the registry- Takahashi N, Kim DW, Kim I, Du X, Lee SE, Hu Y, Kikushige Y, Jiang Q, Wang Y, Chen S, Zhu H, Goto T, Tomita A, Ichii M, Nakamae H, Liu L, Liu B, Malek K, Zhu T, Wu S, Wang J. Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study. Cancer Med. 2026 Jun;15(6):e72019. doi: 10.1002/cam4.72019. PubMed 42339511
- Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Etienne G, Kim I, Andorsky DJ, Bombaci F, Issa GC, Takahashi N, Kapoor S, Jinwal R, Malek K, McCulloch T, Yau L, Larson RA, Hochhaus A. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026 Mar 26;147(13):1433-1446. doi: 10.1182/blood.2025029210. PubMed 41397287
- Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, le Coutre P, Takahashi N, Kim I, Etienne G, Andorsky D, Issa GC, Larson RA, Bombaci F, Kapoor S, McCulloch T, Malek K, Yau L, Ifrah S, Hoch M, Cortes JE, Hughes TP; ASC4FIRST Investigators. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31. PubMed 38820078
- Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, Ramscar N, Ifrah S, Hughes TP. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncol. 2022 Dec;18(38):4161-4170. doi: 10.2217/fon-2022-0923. Epub 2022 Dec 16. PubMed 36524980